Incyte Corp. closed 14.97% short of its 52-week high of $83.95, which the company reached on November 8th.

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up ...

Shares of Incyte Corp. slipped 7.86% to $68.30 Monday, on what proved to be an all-around positive trading session for the ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: ...

Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...